N
Neuron23
A biotech company focused on developing precision medicines for neurological and immunological diseases
About Neuron23
Neuron23 Inc. is a clinical-stage biotechnology startup based in South San Francisco, California. The company is focused on developing precision medicines for genetically defined neurological and immunological diseases. This means they create targeted treatments for specific diseases based on the genetic makeup of the disease and the patient. Their primary market is patients suffering from these specific diseases, including Parkinson's disease.
Read full description
The company operates in the biotechnology and healthcare industry, where it uses advanced technologies like data science and machine learning to discover and develop new drugs. One of their promising projects is a brain-penetrant LRRK2 inhibitor, NEU-723, which is currently in Phase 1 clinical trials. This drug is designed to treat Parkinson's disease and is paired with a first-of-its-kind diagnostic tool that helps identify patients who are likely to respond to the therapy.
Neuron23's business model revolves around the research, development, and commercialization of these precision medicines. They generate revenue through the sales of these drugs once they are approved for use. Additionally, they also collaborate with other companies, like QIAGEN, to develop companion diagnostics, which are tests used to determine the suitability of a particular treatment for a patient.
In summary, Neuron23 is a biotech startup that uses genetic information to develop targeted treatments for neurological and immunological diseases, with a focus on improving patient lives.
At a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- South San Francisco, United States
- Employees
- 28
- Open positions
- None listed
- Dealroom signal
- 63.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Precision Medicine, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Jun 2026 | $2.5M | — | Michael J. Fox Foundation for Parkinson's Research | ↗ |
| SERIES DOther financing | Jun 2025 | $97M | $500M | Kleiner Perkins · Westlake Village BioPartners · SoftBank Vision Fund · Redmile Group | ↗ |
Growth signals
Latest recorded traffic for Neuron23 is 3.5K monthly website visits, up 40% over the last three months. Neuron23's team declined 20% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Michael J. Fox Foundation for Parkinson's Research
Series A8 investors entered at this stage
Cowen Group
Perceptive Advisors
Westlake Village BioPartners
Citadel
Kleiner Perkins
HBM Partners
Redmile Group
Acorn Bioventures
Series B and later5 investors entered at this stage
HBM Healthcare Investments
SoftBank Vision Fund
SoftBank
Surveyor Capital
Blue Owl Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Neuron23 on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Neuron23’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.